Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Qaseem A, Obley AJ, Yost J, Abraham GM, Andrews RA, Jokela JA, Miller MC, Humphrey LL, Haeme R, Krain A, Poonacha T, Saini SD, Wilt TJ, Carroll K, Etxeandia-Ikobaltzeta I, Harrod CS, Shamliyan T, Vigna C. Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3). Ann Intern Med. 2026 Apr; 179(4):559-563.
-
Friedmann PD, Wilson D, de Gijsel D, Nolte K, Dejace J, Hoskinson R, Del Toro-Mejias L, Bianchet E, Dowd P, Soares WE, Stopka TJ. Mobile Telemedicine for Treating Chronic Hepatitis C Among Rural People Who Inject Drugs: A Randomized Clinical Trial. JAMA Netw Open. 2026 Jan 02; 9(1):e2555125.
-
Min EA, Bolduc P. Prevention and Management of Viral Hepatitis in Primary Care. Top Antivir Med. 2025 Dec; 33(6):711-726.
-
Maryam A, Moquin SA, Dovala D, Kaur J, Kurt Yilmaz N, Shaqra AM, Schiffer CA. Structural Analysis of Inhibitor Binding to the Feline Enteric Coronavirus (FECV) Main Protease. Viruses. 2025 Nov 16; 17(11).
-
Ding S, Yang D, Ullah I, Niu L, Unger M, D?az-Salinas MA, Chandravanshi M, Zhou F, Beaudoin-Bussi?res G, Benlarbi M, Tolbert WD, Yoon K-W, Xu R, Laroche G, Gaudette F, Morton AJ, Lang ZC, Son A, Abrams C, C?t? M, Smith AB, Huang RK, Matthies D, Munro JB, Pazgier M, Uchil PD, Finzi A. Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants. J Virol. 2025 11 25; 99(11):e0103425.
-
Ru Y, Ma-Lauer Y, Xiang C, Li P, von Brunn B, Richter A, Drosten C, Pichlmair A, Pfefferle S, Klein M, Damoiseaux RD, Betz UAK, von Brunn A. LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16. Pathogens. 2025 Sep 02; 14(9).
-
Lewis NM, Harker EJ, Grant LB, Zhu Y, Grijalva CG, Chappell JD, Rhoads JP, Baughman A, Casey JD, Blair PW, Jones ID, Johnson CA, Lauring AS, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Shapiro NI, Duggal A, Busse LW, Felzer J, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Hough CL, Wilson JG, Mosier J, Qadir N, Chang SY, Ginde AA, Martinez A, Mohr NM, Mallow C, Harris ES, Johnson NJ, Srinivasan V, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, Goyal A, DeLamielleure LE, DeCuir J, Surie D, Dawood FS, Tenforde MW, Uyeki TM, Garg S, Ellington S, Self WH. Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. Clin Infect Dis. 2025 Aug 01; 81(1):190-197.
-
Meister TL, Nocke MK, Heinen N, Burkard TL, Br?ggemann Y, Westhoven S, Tr?eb B, Ebert N, Thomann L, Lubieniecki KP, Lubieniecka JM, D?ring K, Herrmann M, Haid S, Pietschmann T, Wiegmann B, Tao R, Pfefferle S, Addo MM, Thiel V, Drexler I, Babel N, Phuc Nguyen H, Brown RJP, Todt D, Steinmann E, Pfaender S. Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants. Proc Natl Acad Sci U S A. 2025 Jul 15; 122(28):e2500276122.
-
Zvornicanin SN, Shaqra AM, Flynn J, Carias Martinez H, Jia W, Moquin S, Dovala D, Bolon DN, Kurt Yilmaz N, Schiffer CA. Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50. mBio. 2025 May 14; 16(5):e0406824.
-
Haidar G, Thomas S, Loubet P, Baker RI, Benfield T, Boonyaratanakornkit J, Kiertiburanakul S, Kim AHJ, Longbrake EE, Molina JM, Paredes R, Tucker D, Uriel A, Weinmann-Menke J, Aksyuk AA, Clegg LE, Currie A, Yang H, Flyrin K, Gibbs M, Shroff M, Perez JL, Chang LJ, Cohen TS. Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. Lancet Infect Dis. 2025 Jul; 25(7):813-826.